New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Overview
The Global Pulmonary Arterial Hypertension Market is projected to reach USD 8.1 billion in 2024 which is further anticipated to reach USD 13.2 billion by 2033 at a CAGR of 5.6%.
The PAH market is growing because of trends in pulmonary hypertension incidence and treatment innovations in the PAH market. Pulmonary arterial hypertension or PAH is a chronic, rapidly progressive disorder of the pulmonary circulation where mean pulmonary arterial pressure is raised.
Endothelin receptor antagonists, (ERAs), and prostacyclin analogs have emerged as recent invaluable additions in managing the disease. There is steady growth in worldwide market opportunities, riding diagnosis rates, renewed treatment portfolios, and research & development.
The market is anticipated to expand at this CAGR due to, introducing innovative treatments and growing patients’ awareness.
Click to Request Sample Report and Drive Impactful Decisions: https://dimensionmarketresearch.com/report/pulmonary-arterial-hypertension-market/request-sample/
The US Pulmonary Arterial Hypertension Market
The US Pulmonary Arterial Hypertension Market with an estimated value of USD 2.5 billion in 2024 is projected to increase at a CAGR of 5.3% until reaching USD 4.0 billion by 2033.
The US-based PAH market has notable market growth due to the prevailing PAH rate and advancement of drug-class therapies. New trends consist of the use of endothelin receptor antagonists and prostacyclin analogs together with others under investigation.
More attention is being paid to early detection of disease and patient concordance is being improved. Also, among provinces, hospital pharmacies have the largest market share in the distribution networks in the United States backed by the growth in the healthcare sector. The market is forecasted to sustain the premier position based on increasing awareness and developments.
Important Insights
- Global Market Insights: This market is projected to be valued at USD 8.1 billion in 2024 and is anticipated to reach USD 13.2 billion by 2033.
- S. Market Insights: The U.S. market is forecasted to grow from USD 2.5 billion in 2024 to USD 4.0 billion by 2033, with a CAGR of 5.3%.
- Drug Class Segment Insights: Endothelin receptor antagonists (ERAs) are expected to lead the drug class segment, capturing 36.5% of the market share by 2024.
- Pipeline Insights: Early-stage drug candidates (Phase I & II) will dominate the pipeline analysis segment, holding 63.1% of the market share in 2024.
- Regional Insights: North America is projected to be the largest market, accounting for approximately 37.10% of the global market share in 2024.
- Key Players: Major companies in the global PAH market include Actelion Pharmaceuticals Inc. (Johnson & Johnson), United Therapeutics Corporation, Bayer AG, GlaxoSmithKline Plc., Gilead Sciences Inc., Pfizer Inc., and Bristol Myers Squibb.
- Global Growth Insights: This market is expected to grow at a CAGR of 5.6% during the forecast period.
Latest Trends
- Increasing Prevalence of PAH: An increasing global prevalence of pulmonary arterial hypertension owing to lifestyle diseases and genetic factors drives the need for appropriate treatments for PAH.
- Shift Towards Oral Therapies: Increasing usage of endothelin receptor antagonists (ERAs) and prostacyclin analog oral treatments enhances patient compliance and fuels market growth.
- Advanced Diagnostic Tools: Better diagnostic tools have paved the way for early identification of PAH thus increasing the patient base and encouraging market research.
- Focus on Combination Therapies: Co-therapies which use two kinds of medications including PDE-5 inhibitors and ERAs are today employed in the treatment, making lots of positive effects, and offering new chances.
Pulmonary Arterial Hypertension Market: Competitive Landscape
The pulmonary arterial hypertension market thus has a highly competitive structure with numerous participants including United Therapeutics, Pfizer, Johnson & Johnson, and Gilead Sciences among others who stand out by introducing new PAH therapies.
To enter novel therapies, some of these firms invest in research to introduce new products, especially in ERAs and prostacyclin analogs. In this market, market share can significantly be improved through strategic alliances, mergers, and acquisitions.
Moreover, higher spending on clinical trials as well as emergent drug projects has increased competition among the industry participants.
Some of the prominent market players:
- Johnson & Johnson (Actelion Pharmaceuticals)
- United Therapeutics Corporation
- Bayer AG
- GlaxoSmithKline plc
- Gilead Sciences, Inc.
- Pfizer Inc.
- Bristol Myers Squibb
- Merck & Co., Inc.
- AbbVie Inc.
- Novartis AG
- Arena Pharmaceuticals, Inc.
- Liquidia Corporation
- Other Key Players
Transform your business approach with strategic insights from our report. Get in touch to request our brochure today! : https://dimensionmarketresearch.com/report/pulmonary-arterial-hypertension-market/download-reports-excerpt/
Pulmonary Arterial Hypertension Market Scope
| Report Highlights | Details |
| Market Size (2024) | USD 8.1 Bn |
| Forecast Value (2033) | USD 13.2 Bn |
| CAGR (2024-2033) | 5.6% |
| The US Market Size (2024) | USD 2.5 Bn |
| Historical Data | 2018 - 2023 |
| Forecast Data | 2024 - 2033 |
| Base Year | 2023 |
| Estimate Year | 2024 |
| Segments Covered | By Drug Class, By Type, By Pipeline Analysis, By Route of Administration, By Distribution Channel |
| Regional Coverage | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Market Analysis
Endothelin receptor antagonists (ERAs) are projected to dominate the drug class segment in the pulmonary arterial hypertension market with 36.5% of market share in 2024 due to their efficacy in reducing vascular resistance in the pulmonary arteries.
ERAs help manage the symptoms of PAH by blocking the action of endothelin, a substance that causes blood vessels to constrict. Their proven ability to improve patient outcomes, including increased survival rates, has solidified their widespread use.
Furthermore, ERAs are often preferred as first-line treatments for pulmonary arterial hypertension, offering both oral and intravenous formulations, driving their dominance in this segment.
Pulmonary Arterial Hypertension Market Segmentation
By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Prostacyclin and Prostacyclin Analogs
- Soluble Guanylate Cyclase (SGC) Stimulators
- Calcium Channel Blockers
By Type
- Branded
- Generics
By Pipeline Analysis
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase)
By Route of Administration
- Oral
- Intravenous/ subcutaneous
- Inhalational
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Purchase the Competition Analysis Dashboard Today: https://dimensionmarketresearch.com/checkout/pulmonary-arterial-hypertension-market/
Growth Drivers
- Innovative Drug Development: Research and development in new drug classes including ERAs and prostacyclin analogs is commencing the PAH market’s growth.
- Increased Government Funding: Governments are extending their support to diseases that are rare such as PAH and extending their financial and other assistance for treatment of pulmonary arterial hypertension.
- Rising Awareness Campaigns: Awareness programs about PAH and its symptoms and available treatment options are helping more people to come forward for early diagnosis further enlarging the large number of patients.
- Approval of New Therapies: The PAH market should surge considerably globally due to the regulations to approve the other breakthrough treatments of this disease.
Restraints
- High Cost of Treatment: The cost of PAH treatment and associated drugs including the popular branded drugs makes it impossible for many patients to access these drugs, especially in regions that have not been developed.
- Limited Awareness in Developing Regions: Limited awareness about PAH symptoms and treatment among the general population and the limited access to healthcare information in emerging markets pose threats to the market.
- Side Effects of Therapies: The side effects of current PAH therapies such as nausea and hypotension limit usage of PAH treatments hence the need to improve upon PAH therapies.
- Patent Expiration: As patents for branded drugs expire, the entry of generics could reduce the profitability of branded PAH medications.
Growth Opportunities
- Emerging Markets: Hospitals and clinics’ capacity is an emerging market for PAH drugs since their awareness and diagnosis increased in Asia-Pacific and Latin American countries.
- Biologics and Gene Therapy: Advances in biologics and gene therapies are gathering pace as potential substitutes for the treatment of pulmonary arterial hypertension, presenting fresh market prospects for participants.
- Expansion of Oral Drug Formulations: The use of new formulations with an enhanced safety profile also presents new opportunities to improve patient compliance through new oral formulations that are convenient to use by patients.
- Focus on Pediatric PAH: Additional targeted therapies for pediatric patients with PAH are currently a small but rapidly developing segment for future market potential.
Regional Analysis
North America is the projected largest pulmonary arterial hypertension (PAH) market as it holds 37.10% of the market share in 2024, mainly because of well-established healthcare systems, focus on innovative R&D, and relatively high incidence of PAH.
Some of the world’s most established pharmaceutical organizations are located in the region like United Therapeutics which has led the way and offered new treatment options for PAH.
Also, early diagnosis and availability of new technologies, including ERA and prostacyclin analogs, support market growth. Support from the government of orphan diseases and raising awareness of campaigns also support North America’s leading competitiveness in the global PAH market.
Click to Request Sample Report and Drive Impactful Decisions: https://dimensionmarketresearch.com/report/pulmonary-arterial-hypertension-market/request-sample/
By Region
North America
- The U.S.
- Canada
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Discover additional reports tailored to your industry needs
- Anticipated that the U.S. Market for Acellular Dermal Matrices will reach a market value of 3.7 USD billion in 2024 and will surge higher to USD 9.8 billion by 2033 at a CAGR of 11.4% in the forecast period (2024 - 2033).
- U.S. Central Venous Catheter Market is projected to reach a market value of USD 1,220.4 million in 2024 and is further expected to attain a market value of USD 2,140.1 million by 2033 at a CAGR of 6.4%.
- Sleep Apnea Devices Market will reach the figure of USD 4.8 Billion in 2024 while it is further anticipated that the market will reach the value of USD 8.9 Billion of 2033 at a CAGR of 7.1%.
- Remote Health Monitoring Market is estimated to have a value of USD 7.8 billion in 2024 and is expected to rise to USD 38.1 billion by the end of 2033, maintaining an annual growth rate of 19.3 percent over the forecasted period.
- Penicillium Drug Market is projected to reach a market value of USD 9.6 billion which is further expected to reach a valuation of USD 13.4 billion at a CAGR of 3.8%.
- Medical Polymer Market is estimated to have a value of USD 24.6 billion in 2024 and is expected to rise to USD 50.5 billion by the end of 2033
- medical packaging film market will be valued at USD 8.5 billion in 2024 and will continue to grow to USD 14.7 billion by 2033 at the rate of 6.2% CAGR.
- Medical Imaging Outsourcing Market is expected to reach a value of USD 9.4 billion in 2024, and it is further anticipated to reach a market value of USD 13.5 billion by 2033 at a CAGR of 4.2%.
- Medical Furniture Market is expected to reach a value of USD 29.8 billion in 2024, and it is further anticipated to reach a market value of USD 54.6 billion by 2033 at a CAGR of 7.0%.
- medical bed market is estimated to reach a market value of USD 4.0 billion in 2024, while it is further projected to grow to a market value of USD 7.0 billion in 2033 at a CAGR of 6.2%.
Recent Developments in the Pulmonary Arterial Hypertension Market
- July 2024: United Therapeutics gained FDA approval for a new oral endothelin receptor antagonist (ERA) drug to treat pulmonary arterial hypertension (PAH) patients.
- March 2024: Pfizer reported successful Phase III trial results for its combination PAH therapy, which combines prostacyclin analogs and endothelin receptor antagonists for enhanced treatment efficacy.
- January 2024: Johnson & Johnson expanded its PAH portfolio through the acquisition of a biotech company specializing in innovative prostacyclin therapies for pulmonary hypertension treatment.
- November 2023: Gilead Sciences launched a new formulation of prostacyclin analogs to improve treatment outcomes for patients with pulmonary arterial hypertension (PAH).
- August 2023: Bayer initiated a Phase II trial to evaluate a next-generation PAH treatment drug, aiming to enhance therapeutic efficacy and patient outcomes.
About Dimension Market Research (DMR):
Dimension Market Research (DMR) is a market research and consulting firm based in India & US, with its headquarters located in the USA (New York). The company believes in providing the best and most valuable data to its customers using the best resources analysts work, to create unmatchable insights into the industries, and markets while offering in-depth results of over 30 industries, and all major regions across the world.
We also believe that our clients don’t always want what they see, so we provide customized reports as well, as per their specific requirements to create the best possible outcomes for them and enhance their business through our data and insights in every possible way.
